clinical trial · NCT06310616
A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants
ViiV Healthcare·phase1·completed·n = 26
HIV InfectionsVH4524184Loestrin
brief summary
This study aims to assess any impact of VH4524184 on the pharmacokinetic (PK) profile of an ethinyl estradiol (EE) and norethindrone acetate (NEA) containing oral contraceptive (OC) administered to healthy adult female participants.
started
Mar 6, 2024
primary completion
Aug 15, 2024
completion
Aug 15, 2024
last updated
Dec 10, 2024
official title
A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics of Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol (Loestrin) When Co-administered With VH4524184 in Healthy Adult Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol